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September 4, 2012:947–9of 637]) (p  0.0001). This pattern persisted even when consid-
ering only those with associated ST-segment elevation: 0.5% (3 of
637) of females, 3.3% (28 of 859) of males (p  0.0001). In male
patients, there was a trend toward a lower prevalence of J-point
elevation patterns with increasing age. In female patients, the
reverse was true, although those with associated ST-segment
elevation were present only in the group aged 18 to 29 years.
Our results demonstrate that the prevalence of what has been
termed J-point elevation differs significantly according to the
inclusion (2.1%) or exclusion (29.3%) of STj elevation as defined in
this study. These data are strikingly similar to the results of Uberoi
et al. (8) in a slightly older VA population. Previous reports on
early repolarization that included ST-segment elevation as a
criterion found similar figures of 1% to 5% in the population (e.g., 2).
However, recent reports (e.g., 3) found a larger proportion of
healthy control subjects, ranging from 3% to 33%, manifesting end
QRS notching or slurring, which compares with our 29.3% with all
types of J-point elevation.
The prognostic value of J-point elevation in an apparently
healthy individual remains uncertain, as a significant proportion of
healthy control subjects from various studies exhibit this morphol-
ogy. Our results suggest that the exclusion of STj elevation from
J-point elevation may further decrease its specificity in healthy
individuals.
We have presented data on the prevalence of J-point elevation
with or without STj elevation in an apparently healthy white
population. These results have implications for studies looking at
the significance of J-point elevation and/or what is currently
termed early repolarization. In short, agreed definitions of J-point
elevation, STj, and ultimately what has been termed malignant
early repolarization (4) are required.
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Letters to the Editor
Potential Treatment Influences
and Mechanisms Related to
Asymmetric Dimethylarginine
Control in Heart Failure
We found the fascinating work presented by Shao et al. (1) to be
particularly compelling, as it highlights the physiological impact—and
potential clinical importance—of the endogenous nitric oxide syn-
thase inhibitor asymmetric dimethylarginine (ADMA) and dimethy-
larginine dimethylaminohydrolases (DDAHs) in patients with con-
gestive heart failure. Ongoing research has provided ample evidence
for the prognostic value of ADMA in the setting of cardiovascular
disease, and the enormous breadth of disorders with endothelial
dysfunction as a central component suggests a prominent role for
ADMA in vascular disease progression. By scrutinizing ADMA
production and metabolism paralleling vascular dysfunction with
subsequent heart failure, Shao et al. underscore the role of arginine
dysregulation and elevated ADMA in cardiovascular disease.
There are a few observations in their study (1), however, that warrant
further scrutiny. The authors report a significant treatment difference
between those with congestive heart failure and those with advanced
decompensated heart failure; the former exhibits high angiotensin-
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September 4, 2012:947–9blocker (ARB) use (92%), whereas the frequency of ACEI/ARB use
was significantly less in the advanced decompensated heart failure
group (61%) (p 0.0001). This difference might affect interpretation
of the ADMA findings, because ACEI/ARBs decrease circulating
ADMA levels (2). Moreover, these medications may affect DDAH
expression and/or activity (3). Shao et al. also reported higher
DDAH-1 expression in hearts from patients who had heart failure
but did not have elevated systolic pulmonary artery pressure compared
with controls and heart failure patients who did have elevated systolic
pulmonary artery pressure, suggesting a successful compensatory effect of
DDAH-1 up-regulation. It may be interesting to evaluate ACEI/ARB
treatment differences among these groups.
In addition, the authors (1) note the importance of both ADMA
production and elimination in controlling ADMA and conclude, on
the basis of DDAH and protein arginine methyltransferase expression
patterns, that reduced elimination is likely responsible for the observed
elevated ADMA levels. Although this hypothesis may ultimately be
true, it is worth noting that proteolysis is necessary for ADMA release
and, hence, accumulation. It has been noted that high concentrations
of protein-incorporated ADMA are present in, and proteolytically
released from, erythrocytes (4). Because high protein turnover may yield
reater ADMA release and because heart failure is associated with
achexia, it might be reasonable to consider protein turnover when
valuating ADMA dysregulation in congestive heart failure.
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Reply
We thank Dr. Billecke and colleagues for their interest in our
paper (1) and agree that various treatments may directly or
indirectly affect asymmetric dimethylarginine levels, and based on
our findings we postulated that modulating dimethylarginine
dimethylaminohydrolase-1 activity with pharmacotherapy can be a
potential therapeutic approach. Nevertheless when comparing be-
tween those with chronic versus advanced decompensated heart
failure who were on angiotensin-converting enzyme inhibitors, levels
of methylated arginine metabolites and arginine bioavailability re-
mained significantly different. This suggested that the underlying
disease severity remains an important determinant. Whether proteol-
ysis and protein turnover can contribute to in vivo asymmetric
dimethylarginine release, particularly during catabolic or hemolytic
processes associated with pulmonary venous hypertension in advanced
heart failure, may warrant further investigation.
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